全球同种异体干细胞治疗市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球同种异体干细胞治疗市场 – 行业趋势及 2030 年预测

  • Healthcare
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Allogenic Stem Cell Therapy Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 994.90 Million
Diagram Market Size (Forecast Year)
USD 2,109.50 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

全球同种异体干细胞治疗市场,按产品类型(成体干细胞、人类胚胎干细胞、诱导性多能干细胞)、细胞来源(脂肪组织衍生的间充质干细胞、骨髓衍生的间充质干细胞、脐带血/胚胎干细胞、其他)、应用(肌肉骨骼疾病、伤口、损伤、心血管疾病、手术、胃肠道疾病、其他)、最终用户(治疗公司、细胞和组织库、工具和试剂公司、服务公司)划分 - 行业趋势和预测到 2030 年。

同种异体干细胞治疗市场

 同种异体干细胞治疗市场分析及规模

通过观察干细胞发育成骨骼、心血管系统、神经末梢以及其他器官和组织中的细胞,科学家可以更好地了解疾病和病症的发展方式。干细胞可以生长成新的组织,用于移植和基因工程。研究人员继续更多地了解干细胞及其在再生医学中的应用,这将在 2023-2030 年的预测期内推动市场增长。

Data Bridge Market Research 分析,同种异体干细胞治疗市场在 2022 年的规模为 9.949 亿美元,预计到 2030 年将达到 21.095 亿美元,在 2023 年至 2030 年的预测期内复合年增长率为 9.85%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

同种异体干细胞治疗市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 - 2020)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

产品类型(成体干细胞、人类胚胎干细胞、诱导性多能干细胞)、细胞来源(脂肪组织衍生的间充质干细胞、骨髓衍生的间充质干细胞、脐带血/胚胎干细胞、其他)、应用(肌肉骨骼疾病、伤口、损伤、心血管疾病、手术、胃肠道疾病、其他)、最终用户(治疗公司、细胞和组织库、工具和试剂公司、服务公司)

覆盖国家

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Athersys Inc. (U.S.), Mesoblast Ltd (Australia), Biorestorative Therapies Inc. (U.S.), Pluristem Inc. (Israel), Brainstorm Cell Limited. (U.S.), ViaCyte Inc. (U.S.), Gamida Cell (U.S.), HOPE BIOSCIENCES (U.S.), Cellular Biomedicine Group (U.S.), Smith+Nephew (U.K.), MEDIPOST (South Korea), ANTEROGEN.CO, LTD. (South Korea), NuVasive Inc. (U.S.), RTI Surgical (U.S.), AlloSource (U.S.), JCR Pharmaceuticals Co. Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan)

Market Opportunities

  • Potential of stem cells for drug discovery
  • Increased product launches in the global market

Market Definition

Stem cell therapy, also known as regenerative medicine, uses stem cells or their derivatives to promote the repair response of dysfunctional,diseased, or injured tissue. Stem cells can develop into various types of cells in the body. Pluripotent and multipotent stem cells are the two main types of stem cells. Pluripotent stem cells are replicating cells that develop from embryonic or fetal tissues. Pluripotent stem cells help the cells and tissues develop in three primary germ layers: mesoderm, ectoderm, and endoderm.

Global Allogenic Stem Cell Therapy Market Dynamics

Drivers

• Increasing funding for stem cell research projects

The need for newer and better therapies for auto-immune, neurobiological, and coronary heart disease treatment has increased cumulative research activities and funding for cell-based research. For instance, the University of Sydney was awarded $6.3 million in June 2021 for three projects addressing adult vision loss and cardiovascular events and improving decisions about access to stem cell interventions. In the same year, Stanford physician-researchers were awarded nearly $31 million by the California Institute for Regenerative Medicine to begin first-in-human trials of stem therapies for treating stroke, heart failure, and a type of brain and spinal cord tumor. These are certain factors that propel the growth of the market.

• Rising number of launches

Increased product launches by key market players are expected to drive the market during the forecast period. For instance, LifeCell, a healthcare service provider, introduced an advanced umbilical cord-stem cell collection kit in August 2017 that protects neonatal stem cells from environmental damage and temperature fluctuations.

Opportunities

• Potential of stem cells for drug discovery

The ability to continuously develop functioning adult tissues in culture using directed differentiation opens up new avenues for drug discovery. Before conducting in vivo trials, researchers can create distinct cell lines and then test novel medications on each cell type in vitro to identify potential interactions. This is critical in developing medicines for use in veterinary research because of the possibility of species-specific combinations. The goal is to having the cell lines available for research use that will reduce the need for research animals because in vitro effects on human tissue will provide insight not previously known before the animal testing phase. These all are the factors which are expected to boost the market growth.

Restraints/Challenges

  • Limited awareness regarding treatment

The main factors impeding the growth of the global allogenic stem cell therapy market are a lack of awareness about treatment options and ethical concerns about embryonic stem cells. For instance, according to data published by the National Center for Biotechnology Information, the main factor is the population's fear of unknown therapies and lack of awareness about treatment options. Furthermore, the high cost of the therapies leads to lower adoption, resulting in lower demand for the product globally.

This allogenic stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the allogenic stem cell therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Allogenic Stem Cell Therapy Market

The COVID-19 pandemic had a negative impact on the global allogenic stem cell therapy market due to a decrease in stem cell therapy research and development. The COVID-19 pandemic has caused significant disruption in research, manufacturing, and clinical development, according to the National Center for Biotechnology Information. Clinical trial disruption will erode the quality of clinical evidence for CGTs further, making a reliable HTA on the treatment benefits and economic impacts of CGTs even more difficult.

Furthermore, the current situation of COVID-19 is driving the growth of the market, as research activities for COVID-19 treatment are proceeding. Stem cell therapy may also be a promising treatment option for COVID-19 in the future. For instance, Lineage Cell Therapeutics, received a USD 5 million grant from the California Institute for Regenerative Medicine (CIRM) on May 6, 2020, to support the use of VAC, Lineage's allogeneic dendritic cell therapy, in the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

Recent developments

  • In December 2021, Century Therapeutics, a biotechnology company, collaborated with Bristol Myers Squibb, a pharmaceutical company, and signed a licence agreement to develop and commercialise up to four induced pluripotent stem cell ("iPSC") derived, engineered natural killer cell ("iNK") and T cell ("iT") programmes for hematologic malignancies and solid tumors.

Global Allogenic Stem Cell Therapy Market Scope

The allogenic stem cell therapy market is segmented on the basis of product type, cell source, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

 Cell Source

  • Adipose Tissue-Derived Mesenchymal Stem Cells
  • Bone Marrow-Derived Mesenchymal Stem Cells
  • Cord Blood/Embryonic Stem Cells
  • Others

 Applications

  • Musculoskeletal Disorders
  • Wounds
  • Injuries
  • Cardiovascular Diseases
  • Surgeries
  • Gastrointestinal Diseases
  • Other

 End Users

  • Therapeutic Companies
  • Cell and Tissues Banks
  • Tools and Reagent Companies
  • Service Companies

Allogenic Stem Cell Therapy Market Regional Analysis/Insights

The allogenic stem cell therapy market is analysed and market size insights and trends are provided by country, product type, cell source, application and end users as referenced above.

The countries covered in the allogenic stem cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the allogenic stem cell therapy market due to the improved investment scenario, technological advancements, and high economic growth.

Asia-Pacific is expected to grow at the highest growth rate from 2023 to 2030, owing to the surge in the prevalence of target chronic diseases.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

同种异体干细胞治疗市场还为您提供了详细的市场分析,包括每个国家医疗资本设备支出的增长、同种异体干细胞治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对同种异体干细胞治疗市场的影响。数据涵盖 2011-2021 年的历史时期。

竞争格局和同种异体干细胞治疗市场份额分析

同种异体干细胞治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对同种异体干细胞治疗市场的关注有关。

同种异体干细胞治疗市场的一些主要参与者包括:

    • Athersys Inc.(美国)
    • Mesoblast Ltd(澳大利亚)
    • Biorestorative Therapies Inc.(美国)
    • Pluristem Inc.(以色列)
    • Brainstorm Cell Limited.(美国)
    • ViaCyte Inc.(美国)
    • Gamida Cell(美国)
    • HOPE BIOSCIENCES(美国)
    • 细胞生物医学集团(美国)
    • Smith+Nephew(英国)
    • MEDIPOST(韩国)
    • ANTEROGEN.CO, LTD.(韩国)
    • NuVasive Inc.(美国)
    • RTI 外科 (美国)
    • AlloSource(美国)
    • JCR制药有限公司(日本)
    • 武田药品工业株式会社 (日本) 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Allogenic Stem Cell Therapy Market is projected to grow at a CAGR of 9.85% during the forecast period by 2030.
The future market value of the Allogenic Stem Cell Therapy Market is expected to reach USD 2109.50 million by 2030.
The major players in the Allogenic Stem Cell Therapy Market are Athersys Inc. (U.S.), Mesoblast Ltd (Australia), Biorestorative Therapies Inc. (U.S.), Pluristem Inc. (Israel), Brainstorm Cell Limited. (U.S.), ViaCyte Inc. (U.S.), Gamida Cell (U.S.), etc.
The countries covered in the Allogenic Stem Cell Therapy Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, etc.